The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HNGE | N/A | N/A | N/A | +24% |
| S&P | +12.94% | +86.25% | +13.25% | +17% |
Hinge Health, Inc. engages in the development of technology platform for the treatment of musculoskeletal (MSK) conditions. Its platform addresses a broad spectrum of MSK care, from acute injury to chronic pain and to post-surgical rehabilitation. The company was founded by Daniel Perez and Gabriel Mecklenburg in 2014 and is headquartered in San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $154.21M | 53.3% |
| Gross Profit | $126.20M | 59.2% |
| Gross Margin | 81.84% | 3.1% |
| Market Cap | $3.85B | 0.0% |
| Net Income | -$1.84M | -640.8% |
| EBITDA | -$3.66M | 3.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $261.34M | 0.0% |
| Accounts Receivable | $86.77M | 0.0% |
| Inventory | 33.7 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.85M | 0.0% |
| Short Term Debt | $4.18M | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -1.83% | 0.0% |
| Return On Invested Capital | -13.74% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $81.28M | 0.0% |
| Operating Free Cash Flow | $82.40M | 0.0% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Book | -13.10 | 22.07 | - | ||
| Price to Sales | 8.41 | 7.23 | - | ||
| Price to Tangible Book Value | -10.75 | 35.93 | - | ||
| Enterprise Value to EBITDA | -6.64 | -982.06 | - | ||
| Return on Equity | -2.8% | - | |||
| Total Debt | $11.07M | $10.13M | $9.97M | $9.03M | -42.58% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
